BioSpace News Archive

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) has announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation (“Bausch + Lomb”) as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022 .

AN2 Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) cleared the Company’s Investigational New Drug (IND) application for epetraborole, a once-daily, orally administered investigational treatment for patients with non-tuberculous mycobacterial (NTM) lung disease in December.

Fluidx Medical’s GPX Embolic Device was used to effectively devascularize a large tumor with multiple feeding vessels as part of a multi-center clinical trial.

METiS Therapeutics today announced the appointment of Hongming Chen, Sc.D., as President and Head of Research & Development.

ADC Therapeutics SA today announced it will host a webcast highlighting its ADC platform and solid tumor pipeline on Tuesday, February 8, from 9:00 to 11:00 a.m. ET.

Graybug Vision, Inc. announced the hiring of six new employees who will enhance Graybug’s Research & Development, Regulatory Affairs and Program Management capabilities, as the Company further builds momentum behind its pipeline in 2022.

GT Biopharma, Inc. (NASDAQ: GTBP), announced today that Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim CEO will be participating in a Fireside Chat at the upcoming B. Riley Securities’ Virtual Oncology Conference.

HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the publication of a scientific paper, authored by the Company’s scientific research team, in the peer-reviewed journal, Molecular Therapy.

BioDelivery Sciences International, Inc. announced it expects 2021 total Company net revenues and BELBUCA® net sales to achieve the high end of its previous guidance range, and 2021 EBITDA to come in above its prior guidance range.

AVEO Oncology announced that new efficacy and safety data from the first line of the phase 1b/2 DEDUCTIVE study of FOTIVDA® in combination with IMFINZI® in previously untreated metastatic hepatocellular carcinoma are being presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.